The study drug is a potential new treatment for Ulcerative Colitis (UC) and other inflammatory gastrointestinal tract diseases.

4 nights
1 visits

There are currently over 100,000 people living with ulcerative colitis (UC) in Australia - one of the highest rates in the world!

UC is a type of autoimmune related condition that affects the large intestine & colon. The immune system goes rogue and causes inflammation resulting in symptoms like abdominal pain, fatigue, diarrhoea, and rectal bleeding.

The Combo Study is researching a treatment for UC and other inflammatory gastrointestinal tract diseases. The study medication has been developed by combining 2 already approved drugs, 1 is already used to treat UC and the other is used to treat gastroenteritis and diarrhoea. The medication is given as a single dose - oral tablet.

There are treatments available, but these currently focus on treating symptoms to provide relief to patients, and often cause a lot of side effects. This study will hopefully provide
an effective treatment for UC, with broader clinical benefits, and fewer or less severe side effects.

This clinical trial has been approved by an independent ethics committee, and participants will be reimbursed for their time.

Call us on 1800 243 733 to discuss your eligibility today!

Eligibility

Biological Sex Male or Female
Age 18 - 55 years old
BMI 18.5 – 32 kg/m²
Body Weight At least 50 kg
Medication Not taking any medication (contraceptives okay)
Medical History Nothing significant
Smoking History Non-smokers